v3.22.2.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
| Revenue: | ||||
| Revenue | $ 6,039,853 | $ 501,567 | $ 6,303,252 | $ 1,499,706 |
| Operating expenses: | ||||
| Product cost of sales | 6,362,783 | 6,362,783 | ||
| Research and development | 6,861,470 | 4,381,542 | 15,521,334 | 12,004,084 |
| General and administrative | 5,114,185 | 3,390,093 | 13,781,352 | 11,011,003 |
| Amortization of intangible asset | 316,875 | 666,875 | ||
| In-process research and development impairment | 3,500,000 | 3,500,000 | ||
| Change in fair value of contingent consideration | (3,118,515) | 295,000 | (3,342,515) | 406,000 |
| Total operating expenses | 19,036,798 | 8,066,635 | 36,489,829 | 23,421,087 |
| Loss from operations | (12,996,945) | (7,565,068) | (30,186,577) | (21,921,381) |
| Change in fair value of warrant liability | 1,456 | 6,831 | 10,746 | 2,808 |
| Interest income | 241,638 | 195,344 | 537,513 | 567,307 |
| Unrealized loss on available-for-sale securities | (145,543) | (1,577,174) | ||
| Other expense, net | (411,314) | (185,332) | (548,924) | (440,675) |
| Total non-operating (loss) income | (313,763) | 16,843 | (1,577,839) | 129,440 |
| Net loss before income taxes | (13,310,708) | (7,548,225) | (31,764,416) | (21,791,941) |
| Income tax benefit (expense) | 215,937 | 215,937 | ||
| Net loss | (13,094,771) | (7,548,225) | (31,548,479) | (21,791,941) |
| Net loss - non-controlling interest | (89,421) | (115,505) | (265,256) | (283,846) |
| Net loss attributable to NightHawk Biosciences, Inc. | $ (13,005,350) | $ (7,432,720) | $ (31,283,223) | $ (21,508,095) |
| Net loss per share, basic (in dollars per share) | $ (0.51) | $ (0.30) | $ (1.22) | $ (0.87) |
| Net loss per share, diluted (in dollars per share) | $ (0.51) | $ (0.30) | $ (1.22) | $ (0.87) |
| Weighted-average common shares outstanding, basic (in shares) | 25,613,316 | 25,137,628 | 25,603,481 | 24,828,438 |
| Weighted-average common shares outstanding, diluted (in shares) | 25,613,316 | 25,137,628 | 25,603,481 | 24,828,438 |
| Comprehensive loss: | ||||
| Net loss | $ (13,094,771) | $ (7,548,225) | $ (31,548,479) | $ (21,791,941) |
| Unrealized gain on foreign currency translation | 115,659 | 68,582 | 210,245 | 113,511 |
| Total comprehensive loss | (12,979,112) | (7,479,643) | (31,338,234) | (21,678,430) |
| Comprehensive loss attributable to non-controlling interest | (89,421) | (115,505) | (265,256) | (283,846) |
| Comprehensive loss - NightHawk Biosciences, Inc. | (12,889,691) | (7,364,138) | (31,072,978) | (21,394,584) |
| Product sales | ||||
| Revenue: | ||||
| Revenue | 5,980,993 | 5,980,993 | ||
| Grant revenue | ||||
| Revenue: | ||||
| Revenue | $ 58,860 | $ 501,567 | $ 322,259 | $ 1,499,706 |
| X | ||||||||||
- Definition Change in fair value of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. No definition available.
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
